Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

HNSCC: Update Bulletin [August 2017]

Product Code:
596200746
Publication Date:
August 2017
Format:
PDF
Price:
€975

Gain new KOL insights on the latest events happening in head and neck squamous cell carcinoma (HNSCC): data from the Phase I/II ECHO-202/KEYNOTE-037 study of Incyte’s IDO1 inhibitor epacadostat in combination with Keytruda (pembrolizumab; Merck & Co.) were presented at ASCO 2017; preliminary results from the ongoing Phase I/II ECHO-204 trial of epacadostat plus Opdivo (nivolumab; Bristol-Myers Squibb [BMS]) in patients with solid tumours, including HNSCC, were presented at ASCO 2017; Merck & Co. announced that the Phase III KEYNOTE-040 trial of Keytruda in previously treated patients with recurrent or metastatic HNSCC failed to meet its primary endpoint of overall survival (OS). 

Business Questions:

  • How do KOLs view the data from the Phase I/II ECHO-202/KEYNOTE-037 study of epacadostat in combination with Keytruda?
  • Where will Keytruda/epacadostat be most likely used in the HNSCC treatment algorithm?
  • How do KOLs view the data from the Phase I/II ECHO-204 trial of epacadostat in combination with Opdivo?
  • What potential does Opdivo/epacadostat hold as a treatment approach for HNSCC and where will it be most likely incorporated into the treatment paradigm?
  • How does Keytruda/epacadostat compare with Opdivo/epacadostat as potential combination treatment regimens for HNSCC?
  • How do KOLs interpret the failure of the KEYNOTE-040 trial of Keytruda to meet its primary endpoint of OS and what bearing will this have on its continued use in second-line treatment?



customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved